Bill Lundberg, Merus CEO
May 28, 2024 07:00 AM EDTUpdated 03:11 PM
R&D

#AS­CO24: Merus, tout­ing more Phase 2 da­ta, plots piv­otal head and neck can­cer tri­al in first-line set­ting

Max Gelman

Senior Editor

Merus re­leased ad­di­tion­al head and neck can­cer da­ta from a Phase 2 study on Tues­day af­ter pub­lish­ing an AS­CO ab­stract last week and out­lined plans …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

WuXi AppTec will sell cell and gene ther­a­py busi­ness to pri­vate eq­ui­ty firm

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

Im­munol­o­gy biotech In­ma­gene to join Nas­daq through re­verse merg­er with what's left of Ike­na

A service from the Financial Times